Connor, Clark & Lunn Investment Management Ltd. Biogen Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Biogen Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 88,502 shares of BIIB stock, worth $17.2 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

88,502

Previous 12,037 635.25%

Holding current value

$17.2 Million

Previous $2.6 Million 690.6%

% of portfolio

0.09%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$190.52 - $236.72 $14.6 Million - $18.1 Million	76,465 Added 635.25%	88,502 $20.5 Million
Q1 2024 May 09, 2024	BUY	$212.02 - $267.71 $2.55 Million - $3.22 Million	12,037 New	12,037 $2.6 Million
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $14.7 Million - $16.9 Million	-53,231 Reduced 49.62%	54,037 $15.4 Million
Q1 2023 May 09, 2023	BUY	$256.56 - $292.34 $11.6 Million - $13.2 Million	45,041 Added 72.38%	107,268 $29.8 Million
Q4 2022 Feb 10, 2023	BUY	$252.44 - $306.72 $15.7 Million - $19.1 Million	62,227 New	62,227 $17.2 Million
Q2 2022 Aug 05, 2022	SELL	$187.54 - $223.02 $2.21 Million - $2.63 Million	-11,787 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$193.77 - $244.14 $949,279 - $1.2 Million	4,899 Added 71.12%	11,787 $2.48 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $378,424 - $486,331	-1,690 Reduced 19.7%	6,888 $1.65 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $2.11 Million - $2.75 Million	-7,463 Reduced 46.52%	8,578 $2.43 Million
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $4.05 Million - $6.49 Million	-15,648 Reduced 49.38%	16,041 $5.56 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $14.3 Million - $16.8 Million	-58,936 Reduced 65.03%	31,689 $8.87 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $13.2 Million - $19.8 Million	55,751 Added 159.86%	90,625 $22.2 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $9.47 Million - $10.9 Million	-35,751 Reduced 50.62%	34,874 $9.89 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $8.92 Million - $11.8 Million	34,478 Added 95.38%	70,625 $18.9 Million
Q1 2020 May 13, 2020	SELL	$268.85 - $341.04 $8.75 Million - $11.1 Million	-32,530 Reduced 47.37%	36,147 $11.4 Million
Q4 2019 Feb 12, 2020	SELL	$220.06 - $304.07 $7.98 Million - $11 Million	-36,248 Reduced 34.55%	68,677 $20.4 Million
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $8.65 Million - $9.7 Million	-39,775 Reduced 27.49%	104,925 $24.4 Million
Q2 2019 Aug 07, 2019	BUY	$219.29 - $241.72 $11.6 Million - $12.8 Million	52,825 Added 57.5%	144,700 $33.8 Million
Q1 2019 May 08, 2019	BUY	$216.71 - $338.96 $17.6 Million - $27.5 Million	81,275 Added 766.75%	91,875 $21.7 Million
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $6.6 Million - $8.36 Million	-23,700 Reduced 69.1%	10,600 $3.19 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $3.86 Million - $5.05 Million	13,150 Added 62.17%	34,300 $12.1 Million
Q2 2018 Aug 02, 2018	SELL	$257.52 - $306.91 $2.45 Million - $2.92 Million	-9,500 Reduced 31.0%	21,150 $6.14 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $4.03 Million - $5.7 Million	15,500 Added 102.31%	30,650 $8.39 Million
Q4 2017 Feb 09, 2018	BUY	$307.64 - $344.58 $930,611 - $1.04 Million	3,025 Added 24.95%	15,150 $4.83 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $126,517 - $148,360	450 Added 3.85%	12,125 $3.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	11,675	11,675 $3.17 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Biogen Inc. Transaction History